ReviewFrontiers in oncology2024
Risk factors for the development of cervical cancer: analysis of the evidence.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Synergistic Interaction Between HPV-16 E7 Oncoprotein and Severe Vitamin A Deficiency in Regulating Adaptive Immunity in a Preclinical Cervical Cancer Model.Journal of medical virology · 2026Article
- Prevalence and genotype distribution of human papillomavirus (HPV) in an at-risk and suspected population in Iran.BMC infectious diseases · 2026Article
- A novel programmed-cell-death-related prognostic risk model for cervical cancer based on mitochondrial genes.Translational cancer research · 2026Article
- Beyond Human Papillomavirus (HPV): Detection of EBV and Polyomaviruses in Cervical and Anal Samples.Journal of medical virology · 2026Article
- The eIF3a/m6A/ENO1 axis orchestrates glycolytic reprogramming and cell growth in cervical cancer.Journal of bioenergetics and biomembranes · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer: A Nationwide Cohort Study.Cancers · 2026Article
- The correlation between the systemic immune-inflammation index and relapse and metastasis in cervical squamous cell carcinoma patients over 50 years and older.BMC immunology · 2026Article
- Integrative molecular diagnostics for HPV-driven cervical carcinogenesis: a translational review of mechanisms and multimodal risk stratification.Frontiers in oncology · 2026Review
- Evaluation of the Association of TNF-α rs361525 Gene Polymorphism in Bangladeshi Patients With Breast and Cervical Cancer: A Case-Control Study and Meta-Analysis.Health science reports · 2025Article
- Evaluation of the Frequency and Patterns of Cervical Cancer Recurrence After Treatment Using ^18F-FDG PET-CT: A Cross-Sectional Study.Health science reports · 2025Article
- AI-Driven predictive modeling of cervical intraepithelial neoplasia severity: a comprehensive analysis with clinical adoption frameworks.BMC cancer · 2025Article
- Observational
- Cervical Cancer in the Era of HPV: Translating Molecular Mechanisms into Preventive Public Health Action.International journal of molecular sciences · 2025Review
- Screening for Cervical Cancer and Early Treatment (SCCET) Project-The Programmatic Data of Romanian Experience in Primary Screening for High-Risk HPV DNA.Diagnostics (Basel, Switzerland) · 2025Article
- Vaginal Adsorbent Gel as a Therapeutic Agent: Is a New Era Beginning for HPV?Journal of clinical medicine · 2025Article
- Factors Associated with Cervical Cancer Screening among Women at Selected District Hospital, Rwanda.Rwanda journal of medicine and health sciences · 2025Article
- Human Papillomavirus and Other Relevant Issues in Cervical Cancer Pathogenesis.International journal of molecular sciences · 2025Review
- Prioritizing the risk of cervical cancer: findings from the SCCUT Multicentre Initiative.Journal of medicine and life · 2025Article
- HPV-Associated Sexually Transmitted Infections in Cervical Cancer Screening: A Prospective Cohort Study.Viruses · 2025Observational
- The Relationship Between Cervicovaginal Infection, Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia in Romanian Women.Diseases (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cervical cancer (CC) is the fourth most prevalent female cancer globally. Understanding its epidemiology is crucial for devising practical strategies suited to geographic and social contexts to attain the global eradication of CC. Hence, this study examined the latest evidence of risk factors contributing to CC development. Methods: An independent literature search was conducted on PubMed using MESH terms. The primary sources were meta-analyses published from 2010 to 2023, which detail updated evidence on risk factors associated with CC. Additionally, the quality of the evidence was evaluated using the GRADE system and recommendations were made accordingly. Results: The main risk factors related to the cause of CC include co-infections with other sexually transmitted infections, genetic markers, cervicovaginal microbiota, nutritional factors, comorbidities that affect the immune response, smoking, and the use of hormonal contraceptives with a quality evidence based on the GRADE scale moderate. Conclusions: Since the necessary cause for CC is persistent cervicovaginal HPV, all the risk factors implicated in the causality of CC act as non-independent cofactors that increase the risk of CC. Thus, changes in public policies aimed at addressing these risk factors are highly recommended and can substantially decrease the risk of CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.